Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose to Participate in Upcoming Investor Conferences

Mar 03, 2016 5:00pm EST

Aptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference

Feb 18, 2016 5:00pm EST

Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting

Dec 03, 2015 8:00am EST

Aptose Biosciences to Participate in Upcoming Investor Conferences

Nov 30, 2015 5:00pm EST

Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures

Nov 20, 2015 7:30am EST

Aptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015

Nov 10, 2015 4:05pm EST

Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents

Nov 10, 2015 8:30am EST

Beat AML & Aptose Biosciences Present Data for APTO-253 at the 57th American Society of Hematology (ASH) Annual Meeting

Nov 05, 2015 9:15am EST

Aptose Biosciences to Host Third Quarter Ended September 30, 2015 Financial Results Conference Call and Webcast

Nov 05, 2015 8:00am EST

Aptose Biosciences to Present at the 2015 BIO Investor Forum

Oct 15, 2015 5:00pm EDT
RSS
  • Prev
    • 1...
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    Next
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences